Sunday, November 8, 2026

USD/EUR Over 2% Down In The Last 21 Sessions

USD/EUR Over 2% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.72% for the last 21 sessions. At 05:13 EST on Monday, 17 April, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 0.886% up from its 52-week low and 13.099% down from its 52-week high.

News about

  • Eur/usd faces barricades around 1.1000 as chances for fed’s rate hike remain stubborn. According to FXStreet on Sunday, 16 April, "The EUR/USD pair is struggling to extend its recovery above the psychological resistance of 1.1000 in the early Asian session. "
  • Eur/usd price analysis: extends pullback from one-year high to 1.0970 horizontal support. According to FXStreet on Monday, 17 April, "Even if the EUR/USD buyers manage to cross the 1.1040 hurdle, the latest peak of 1.1075 appears a tough nut to crack for them ahead of challenging the late March 2022 high of near 1.1185.", "Adding strength to the downside bias is the previous day's EUR/USD decline below the horizontal area comprising multiple levels marked since early February, as well as a one-week-old ascending trend line."
  • Eur/usd rebound approaches 1.1000 as US dollar fades recovery, ecb’s lagarde, pmis in focus. According to FXStreet on Monday, 17 April, "Moving on, ECB President Lagarde is scheduled to speak one more time in the day and can entertain EUR/USD traders. ", "On the other hand, the market's pricing of the ECB's 0.25% rate hike and the policymakers' resistance to utter policy pivot or rate cut, except Governing Council member Mario Centeno, also keeps the EUR/USD buyers hopeful. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com